JP2017511324A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511324A5
JP2017511324A5 JP2016559965A JP2016559965A JP2017511324A5 JP 2017511324 A5 JP2017511324 A5 JP 2017511324A5 JP 2016559965 A JP2016559965 A JP 2016559965A JP 2016559965 A JP2016559965 A JP 2016559965A JP 2017511324 A5 JP2017511324 A5 JP 2017511324A5
Authority
JP
Japan
Prior art keywords
adjuvant
composition
immunogenic composition
rts
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511324A (ja
JP6645982B2 (ja
Filing date
Publication date
Priority claimed from GBGB1405921.6A external-priority patent/GB201405921D0/en
Application filed filed Critical
Publication of JP2017511324A publication Critical patent/JP2017511324A/ja
Publication of JP2017511324A5 publication Critical patent/JP2017511324A5/ja
Application granted granted Critical
Publication of JP6645982B2 publication Critical patent/JP6645982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559965A 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法 Active JP6645982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405921.6 2014-04-02
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (3)

Publication Number Publication Date
JP2017511324A JP2017511324A (ja) 2017-04-20
JP2017511324A5 true JP2017511324A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6645982B2 JP6645982B2 (ja) 2020-02-14

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法

Country Status (18)

Country Link
US (3) US10688168B2 (cg-RX-API-DMAC7.html)
EP (2) EP3125930B1 (cg-RX-API-DMAC7.html)
JP (2) JP6655549B2 (cg-RX-API-DMAC7.html)
KR (2) KR102762440B1 (cg-RX-API-DMAC7.html)
CN (2) CN106456738B (cg-RX-API-DMAC7.html)
AR (1) AR099960A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015239025B2 (cg-RX-API-DMAC7.html)
BE (1) BE1022355B1 (cg-RX-API-DMAC7.html)
BR (2) BR112016022463A2 (cg-RX-API-DMAC7.html)
CA (2) CA2943007C (cg-RX-API-DMAC7.html)
EA (1) EA037405B1 (cg-RX-API-DMAC7.html)
ES (2) ES2961840T3 (cg-RX-API-DMAC7.html)
GB (1) GB201405921D0 (cg-RX-API-DMAC7.html)
IL (1) IL247493B (cg-RX-API-DMAC7.html)
MX (3) MX2016012982A (cg-RX-API-DMAC7.html)
SG (1) SG11201607086QA (cg-RX-API-DMAC7.html)
WO (2) WO2015150568A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605955B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2594758T3 (es) 2002-10-23 2016-12-22 Glaxosmithkline Biologicals S.A. Procedimientos de vacunación contra la malaria
MX2007004031A (es) 2004-10-14 2007-11-08 Crucell Holland Bv Vacunas de cebado/refuerzo contra el paludismo.
EP2457926B1 (en) * 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
MX2009009342A (es) * 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
ES2647321T3 (es) * 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
LT2315834T (lt) * 2008-07-25 2018-09-10 Glaxosmithkline Biologicals S.A. Tuberkuliozės rv2386c baltymas, kompozicijos ir jų panaudojimas
HUE031044T2 (en) * 2008-07-25 2017-06-28 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
HUE045766T2 (hu) * 2010-12-14 2020-01-28 Glaxosmithkline Biologicals Sa Antigén mycobacterium-készítmény
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
BR112016023778A2 (pt) * 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Similar Documents

Publication Publication Date Title
JP2017511324A5 (cg-RX-API-DMAC7.html)
Garçon et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
EP3089754B1 (en) Single vial vaccine formulations
JP2017511327A5 (cg-RX-API-DMAC7.html)
TW200722101A (en) Novel composition
HRP20230359T1 (hr) Imunogeni pripravak
HUE031740T2 (en) A vaccine composition comprising a synthetic adjuvant
Rosas et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres
Lowell et al. Back to the future: immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
US11951161B2 (en) Methods for inducing an immune response
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
JP2015520196A5 (cg-RX-API-DMAC7.html)
JP2018532782A5 (cg-RX-API-DMAC7.html)
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
EP3389698B1 (en) Dried composition
Mishra et al. Adjuvant effect of aqueous extract of Rhodiola imbricata rhizome on the immune responses to tetanus toxoid and ovalbumin in rats
Precioso et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems
Al Saleh et al. MicroCrystalline Tyrosine-adsorbed immunotherapy
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
EP4421174A3 (en) Adjuvant comprising a glycoarchaeol and an immunostimulant
US10973900B2 (en) Dried composition
WO2022076723A8 (en) Imdq-peg-chol adjuvant and uses thereof
Kanchan et al. Role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens
WO2021101187A3 (ko) 바바킨을 포함하는 신규 백신용 면역보조제 조성물